Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06169722 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 26, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Enrollment target: 120 to 60 Primary completion date: Feb 2025 to Feb 2026 · Trial status: Recruiting to Active, Not Recruiting · Site details revisedv3 Show 3 more changesShow less
    • Primary completion date: Feb 2025 to Feb 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jan 2025 to Feb 2025 · Start date changed from estimate of Jan 2024 to Feb 6, 2024 · Eligibility criteria expanded, about 77 words · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Jan 2025 to Feb 2025
    • Start date changed from estimate of Jan 2024 to Feb 6, 2024
    • Eligibility criteria expanded, about 77 words
    • Study description expanded, about 43 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2. Phase II study stage: Primary objective: To evaluate the efficacy Secondary objectives: To evaluate the safety
Trial Details
NCT Number NCT06169722
Lead Sponsor Beijing Tide Pharmaceutical Co., Ltd
Conditions GVHD, Chronic
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov